GSK481
目录号: A12615
RIP1 抑制剂
GSK481 是一种新型的苯并噁唑酮(BOAz)系列的 RIP1 抑制剂。受体相互作用蛋白激酶1(RIP1)被认为是通过调节程序性坏死来促进炎症的关键因素。抑制这种激酶已被证明可以阻碍细胞坏死性死亡,从而确定 RIP1 作为多种炎症性疾病潜在治疗的可行靶点。
Discription | GSK481 is a novel benzoxazepinone (BOAz) series of RIP1 inhibitors. Receptor Interacting Protein Kinase 1 (RIP1) has been implicated as a key contributor to inflammation through the regulation of programmed necrosis. Inhibition of this kinase has been shown to hinder cell necrotic death, thereby establishing RIP1 as a viable target for the potential treatment of multiple inflammatory diseases. | |||||
---|---|---|---|---|---|---|
Targets |
|
|||||
Cell Research |
|
目录号 | A12615 |
---|---|
分子式 | C21H19N3O4 |
分子量 | 377.39 |
CAS号 | 1622849-58-4 |
SMILES | O=C(C1=NOC(CC2=CC=CC=C2)=C1)N[C@H]3COC4=CC=CC=C4N(C)C3=O |
其他名称 | GSK 481, GSK-481 |
储存条件 | Store lyophilized at -20ºC, keep desiccated. |
In vitro | DMSO | 70 mg/mL (185.48 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 26.5 mL | 132.49 mL | 264.98 mL |
0.5 mM | 5.3 mL | 26.5 mL | 53 mL |
1 mM | 2.65 mL | 13.25 mL | 26.5 mL |
5 mM | 0.53 mL | 2.65 mL | 5.3 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2